ClinicalTrials.gg
TerminatedNCT00905437Updated Jan 28, 2021Results posted

Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement

A Phase 3 interventional study of Placebo and Pregabalin in Pain, Perioperative, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 7 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Supportive care

Why this study was terminated
The Study was terminated on May 24th 2012 due to a slow recruitment rate. The study was not terminated for reasons of safety or efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 55 studies testing pregabalin in Pain — 4 open to participants now, 4 under way, none of them phase 3. Pregabalin · Pain.

Enrollment
26th of 55
72 · median 64
Started
2009
with 3 others
Phase 3
15 of 55
none open now
Registered
18th of 55
by date
Lead sponsor
9 of 55
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 55 studies testing pregabalin in Pain, this one is the 26th largest by enrollment, is one of 4 that started in 2009, is one of 15 in phase 3, and was the 18th registered.

Pain

10,075 studies on the registry are indexed under Pain; 1,649 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 55 studies testing pregabalin in Pain are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 929 Pain studies recruiting now, 384 (41%) set no upper age limit and 433 (47%) stop at 75 or younger; 145 take children under 18; 220 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing pregabalin in Pain, or all of them as a file.
02

Study summary

The purpose of this study is the investigate if pregabalin started a day before surgery and continued for 14 days post-operatively can reduce post-operative pain, relieve pre- and post-operative anxiety and sleep disturbances.

03

Conditions studied

  • Pain, Perioperative

Keywords

  • perioperative
  • pregabalin
  • total hip replacement
  • post-operative pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is undergoing a routine (i.e., expected to be uncomplicated) total primary or secondary hip replacement surgery performed under a standardized regimen of spinal anesthesia, and is expected to experience moderate to severe post-surgical pain in the absence of post-operative analgesia

Exclusion criteria

Exclusion Criteria:

  • The patient is undergoing a revision to a previous hip replacement procedure, hip replacement procedure further to a road traffic accident with multiple injuries, or a procedure expected to last longer than 4 hours
  • The patient has a history of uncontrolled chronic disease or a concurrent illness or medical condition, which in the Investigator's opinion, would contraindicate study participation or confound interpretation of the results
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo as an adjunct to standard of care

    Drug: Placebo

  • Active comparator
    Pregabalin

    Pregabalin as an adjunct to standard of care

    Drug: Pregabalin

Interventions

  • DrugPlacebo

    Placebo as an adjunct to standard of care

  • 75 mg BD for 14 days

06

What researchers measure

Primary outcomes

  1. Mean Pain on Movement Score

    Mean pain on movement score was defined as the mean of the pain on movement score over Days 1 to 5 post-surgery. Pain experienced by participant during passive flexion through 90 degree and passive abduction through 30 degree at operated hip joint was evaluated on a scale of 0 to 10 where, 0= no pain and 10= worst possible pain.

    Time frame: Every 12 hours from Day 1 to Day 5 post-surgery

Secondary outcomes

  1. Mean Daily Pain Score

    Mean daily pain score was defined as the mean of daily pain score over Days 1 to 7 and Days 8 to 14 post-surgery. Daily Pain Rating Scale (DPRS): participant rated 11-point Likert scale ranging from 0 (no pain) to 10 (worst possible pain) during past 24-hour period. Higher score indicates greater level of pain.

    Time frame: Day 1 to Day 7, Day 8 to Day 14 post-surgery

  2. Mean Daily Sleep Interference Score

    Mean daily sleep interference score was defined as the mean of daily sleep interference numeric rating scale (NRS) score over Days 1 to 5 post-surgery. Daily Sleep Interference Scale (DSIS): participant rated pain during past 24-hour period on NRS ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication.

    Time frame: Day 1 to Day 5 post-surgery

  3. Mean Anxiety Visual Analogue Scale (A-VAS)

    Mean anxiety visual analogue scale (VAS) was defined as the mean of VAS score on the day of surgery and over Days 1 to 5 post-surgery. Participants measured their degree of anxiety over past 24 hours on a VAS of 0 to 100, where 0 = not at all anxious to 100 = extremely anxious.

    Time frame: Day 0 to Day 5 post-surgery

  4. Time to Mobilization After Surgery

    Participant was encouraged each day (from Day 3) to attempt walking depending upon the degree of pain on standing. The first day on which the participant was able to walk for 5 steps was the day of mobilization. Median time to mobilization (in hours) was calculated till the day of mobilization.

    Time frame: Day 1 to Day 5 post-surgery

  5. Number of Participants With Rescue Medication Usage

    Rescue medications were used for participants with moderate or severe resting pain. Fentanyl injection (25 microgram \[mcg\] intravenous bolus to a maximum dose of 3 milliliter/day), paracetamol tablet (15 milligram/kilogram orally to a maximum dose of 45 milligram/kilogram/day) were used as rescue medications.

    Time frame: Day 0 to Day 6 post-surgery

  6. Number of Participants With Neuropathic Pain

    ID Pain questionnaire was used to assess neuropathic pain. 6 items questionnaire, did pain feel like: (1)pins and needles (2)hot/burning (3)numb (4)electrical shocks (5)is pain made worse with touch of clothing or bed sheets (6)is pain limited to your joints. "Yes" response to questions 1-5 were scored as 1, while a "yes" response to question 6 was scored as -1. "No" response were scored as 0. Overall score range -1 to 5.Higher score more indicative of pain with a neuropathic component. Number of participants with score 2 or more (which indicated nerve pain) were reported.

    Time frame: Day 90, Day 180 post-surgery

07

Results

Posted Jun 11, 2013
Limitations and caveats
As the enrollment rate was very low, the study was prematurely terminated. The number of enrolled participants was too low for meaningful formal statistical conclusions.

Participant flow

Participant flow — Overall Study
MilestonePregabalinPlacebo
Started3537
Completed2727
Not completed810
Withdrew: Adverse event32
Withdrew: Lost to follow-up01
Withdrew: Withdrawal by subject01
Withdrew: Other56

Outcome measures

PrimaryMean Pain on Movement Score

Mean pain on movement score was defined as the mean of the pain on movement score over Days 1 to 5 post-surgery. Pain experienced by participant during passive flexion through 90 degree and passive abduction through 30 degree at operated hip joint was evaluated on a scale of 0 to 10 where, 0= no pain and 10= worst possible pain.

Time frame:
Every 12 hours from Day 1 to Day 5 post-surgery
Reported as:
Mean · Units on a scale
Mean Pain on Movement Score
Units on a scalePregabalinPlacebo
Mean Pain on Movement Score4.0 ± 0.233.9 ± 0.26
SecondaryMean Daily Pain Score

Mean daily pain score was defined as the mean of daily pain score over Days 1 to 7 and Days 8 to 14 post-surgery. Daily Pain Rating Scale (DPRS): participant rated 11-point Likert scale ranging from 0 (no pain) to 10 (worst possible pain) during past 24-hour period. Higher score indicates greater level of pain.

Time frame:
Day 1 to Day 7, Day 8 to Day 14 post-surgery
Reported as:
Mean · Units on a scale
Mean Daily Pain Score
Units on a scalePregabalinPlacebo
Days 1 to 7 (n=27,30)2.6 ± 0.232.6 ± 0.24
Days 8 to 14 (n=26,27)1.8 ± 0.251.4 ± 0.25
SecondaryMean Daily Sleep Interference Score

Mean daily sleep interference score was defined as the mean of daily sleep interference numeric rating scale (NRS) score over Days 1 to 5 post-surgery. Daily Sleep Interference Scale (DSIS): participant rated pain during past 24-hour period on NRS ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep). Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication.

Time frame:
Day 1 to Day 5 post-surgery
Reported as:
Mean · Units on a scale
Mean Daily Sleep Interference Score
Units on a scalePregabalinPlacebo
Mean Daily Sleep Interference Score2.6 ± 0.343.1 ± 0.29
SecondaryMean Anxiety Visual Analogue Scale (A-VAS)

Mean anxiety visual analogue scale (VAS) was defined as the mean of VAS score on the day of surgery and over Days 1 to 5 post-surgery. Participants measured their degree of anxiety over past 24 hours on a VAS of 0 to 100, where 0 = not at all anxious to 100 = extremely anxious.

Time frame:
Day 0 to Day 5 post-surgery
Reported as:
Mean · Units on a scale
Mean Anxiety Visual Analogue Scale (A-VAS)
Units on a scalePregabalinPlacebo
Mean Anxiety Visual Analogue Scale (A-VAS)23.3 ± 3.3324.7 ± 2.88
SecondaryTime to Mobilization After Surgery

Participant was encouraged each day (from Day 3) to attempt walking depending upon the degree of pain on standing. The first day on which the participant was able to walk for 5 steps was the day of mobilization. Median time to mobilization (in hours) was calculated till the day of mobilization.

Time frame:
Day 1 to Day 5 post-surgery
Reported as:
Median · hours
Time to Mobilization After Surgery
hoursPregabalinPlacebo
Time to Mobilization After Surgery72.500 (51.250 to 76.167)52.417 (46.750 to 73.250)
SecondaryNumber of Participants With Rescue Medication Usage

Rescue medications were used for participants with moderate or severe resting pain. Fentanyl injection (25 microgram \[mcg\] intravenous bolus to a maximum dose of 3 milliliter/day), paracetamol tablet (15 milligram/kilogram orally to a maximum dose of 45 milligram/kilogram/day) were used as rescue medications.

Time frame:
Day 0 to Day 6 post-surgery
Reported as:
Number · participants
Number of Participants With Rescue Medication Usage
participantsPregabalinPlacebo
Number of Participants With Rescue Medication Usage1725
SecondaryNumber of Participants With Neuropathic Pain

ID Pain questionnaire was used to assess neuropathic pain. 6 items questionnaire, did pain feel like: (1)pins and needles (2)hot/burning (3)numb (4)electrical shocks (5)is pain made worse with touch of clothing or bed sheets (6)is pain limited to your joints. "Yes" response to questions 1-5 were scored as 1, while a "yes" response to question 6 was scored as -1. "No" response were scored as 0. Overall score range -1 to 5.Higher score more indicative of pain with a neuropathic component. Number of participants with score 2 or more (which indicated nerve pain) were reported.

Time frame:
Day 90, Day 180 post-surgery

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—2/35 (5.7%)23/35 (65.7%)
Placebo—0/37 (0%)22/37 (59.5%)
Most frequent serious events
Most frequent serious events
EventPregabalinPlacebo
Oxygen saturation decreasedInvestigations1/350/37
AsthmaRespiratory, thoracic and mediastinal disorders1/350/37
HypotensionVascular disorders1/350/37
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPregabalinPlacebo
PyrexiaGeneral disorders16/3510/37
ConstipationGastrointestinal disorders3/353/37
CoughRespiratory, thoracic and mediastinal disorders3/351/37
VomitingGastrointestinal disorders2/353/37
Haemoglobin decreasedInvestigations0/353/37
PainGeneral disorders2/352/37
HeadacheNervous system disorders2/351/37
HypotensionVascular disorders2/352/37
Back painMusculoskeletal and connective tissue disorders1/352/37
DiarrhoeaGastrointestinal disorders1/351/37

Baseline characteristics

Age, Continuous
Age, Continuous(years)PregabalinPlaceboTotal
Mean47.1 ± 13.548.9 ± 13.348.0 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinPlaceboTotal
Female152035
Male201737
08

Study locations

7 sites
  • Pfizer Investigational Site
    Hyderabad, Andhra Pradesh 500 033, India
  • Pfizer Investigational Site
    Ahmedabad, Gujarat 380 015, India
  • Pfizer Investigational Site
    Bangalore, Karnataka 560 076, India
  • Pfizer Investigational Site
    Kanpur, Uttar Pradesh, 208 001, India
  • Pfizer Investigational Site
    Kanpur, Uttar Pradesh 208 002, India
  • Pfizer Investigational Site
    Kolkata, West Bengal 700 054, India
  • Pfizer Investigational Site
    New Delhi, 110 017, India
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2009
First posted
May 20, 2009
Start
Nov 2009
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Jun 11, 2013
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00905437
Responsible party
Sponsor
First posted
May 20, 2009
Start date
Nov 2009
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Jun 11, 2013
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion